David Meeker adds another biotech board spot to the post-Genzyme resume; J&J’s DePuy acquires 3D printing tech for bone healing

David Meeker

→ Soon-to-be-ex-Genzyme head David Meeker has added another biotech board position to his resume. Just a few days after being named chairman at Rhythm, South San Francisco-based MyoKardia has named Meeker to the board. Meeker will be leaving Genzyme after a long career in June.

J&J’s DePuy Synthes Products has acquired 3D printing technology from Tissue Regeneration Systems. DePuy plans to use the technology to “create patient-specific, bioresorbable implants with a unique mineral coating intended to support bone healing in patients with orthopedic and craniomaxillofacial deformities and injuries.” Financial terms of the transaction have not been disclosed.

Atara Biotherapeutics, which is working on allogeneic T cell therapies, signed a 15-year lease of an approximately 90,000-square-foot building, the second largest in SRG’s 507,878-square-foot project in Thousand Oaks, Ca.

→ Cambridge, MA-based H3 Biomedicine is extending its collaboration with Foundation Medicine in search of new cancer drivers.

→ The European Commission has a one-word response to the UK’s insistence that it can still keep the EMA in London after the country exits the EU: Forgetaboutit. “The United Kingdom is leaving the European Union and it will have no say in the location of EU agencies,”said an EC spokesperson.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->